金城医药：子公司收到药品补充申请批准通知书

Core Viewpoint - The company announced that its subsidiary, Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the supplemental application of injectable Cefoperazone Sodium and Sulbactam Sodium [2] Group 1 - The approval is significant for the company's product portfolio and may enhance its market position in the pharmaceutical industry [2] - The injectable form of Cefoperazone Sodium and Sulbactam Sodium is expected to meet the growing demand for effective antibiotics in the healthcare sector [2]